Results Presentation
1Q of FY Ending March 2024
WIN-Partners Co., Ltd. (3183)

1Q results to June 2023

Highlights⚫ Sales in major segments increased YoY⚫ Gross profit margin improved YoY due to increased
sales and reinforced negotiations with suppliers⚫ Operating profit decreased YoY due to increased SGA
expenses which were partly inflated by newly
consolidated subsidiaries3Consolidated results summary（¥ mil.）1Q toJun. 2022

Jun. 2023

YoY(%)

Sales16,744+3.8

Operating profit

557

Recurring profit

558

Net profit

400

EPS (yen)14.11

17,383
432
435
290
10.23

BPS (yen)743.58761.81

-22.5
-22.0
-27.5
－－4

SalesYoY+3.8%(¥ mil.)16,744

17,383

1Q to Jun. 2022

1Q to Jun. 2023⚫

PCI sales increased YoY⚫

In the CRS segment, on which WIN has been focusing,
ABL-related sales continued growing⚫

SHD-related sales remained a driving force behind sales
growth in the CVS segment
5Sales breakdown by segment (YoY)
Segment

Sales（¥ mil.）YoY growth (%)
VolumeValue% of sales(%)

Percutaneous coronary intervention (PCI)

4,308+5.1+3.6

24.8

Cardiac rhythm segment (CRS)

4,776+8.0+7.4

27.5

Cardiac vascular segment (CVS)

3,043

+8.0

+16.9

17.5

Percutaneous peripheral intervention (PPI)

1,094+7.7+10.9

6.3

Neurovascular

910

+26.8

+25.0

5.2

Diabetes mellitus segment (DMS)

851

-+7.4

4.9

Medical equipment

914--44.4

5.3

1,485-+7.3

8.5

17,383

-+3.8

100.0

OthersTotal6Operating profit
YoY-22.5%(¥ mil.)557

432

1Q to Jun. 2022

1Q to Jun. 2023

⚫ Gross profit margin 12.4% (+0.5 pp YoY)
- Sales in the major segments increased YoY- Negotiations with suppliers were reinforced⚫ SGA +20.2% YoY- Impact of newly consolidated TOSAY Medical and TRYTECH- Labor, travel, and PR (related to the 10 anniversary) costs increased- Number of employees: 565 (Jun. 2022) → 634 (Jun. 2023)
7

Introduction of New Outside Director

Etsuko Takamura
May 1979

Residency, Department of Ophthalmology, Tokyo Women’s Medical University, Schoolof Medicine

June 1998

Assistant Professor (currently Associate Professor), Department of Ophthalmology,Tokyo Women’s Medical University, School of Medicine

November 2010

Clinical Professor, Department of Ophthalmology, Tokyo Women’s Medical University,
School of Medicine

April 2014

Auditor, Japanese Ocular Allergy Society (present)

April 2018

Professor, Department of Ophthalmology, Tokyo Women’s Medical University, Schoolof Medicine

April 2020

Part-time engagement, Department of Ophthalmology, Tokyo Women’s MedicalUniversity, School of Medicine (present)

June 2020

Distinguished Member, Japanese Society of Allergology (present)

September 2021

Advisor, Japanese Society for Sjogren’s Syndrome (present)

8Initiatives for human capital
We set the following KPIs to promote the development of human resources that
support sustainable corporate activities and diversity to enable employees todemonstrate their skills & talents
KPI

Actual(3/2023 %)Target(3/2024 %)Utilization rate of staggered working hours and flextime

60

65

Utilization rate of level-based education lessons andeducation tools for self-enlightenment

5860

Maintain 25% female employment ratio

3925

Percentage of promotion-to-manager recommendations
for female employees

3120

Participation of female employees in KIRARIS meetings (asupport team for female employees)

9580

Percentage of male employees taking childcare leave

3745

Thorough education on compliance and human rights(Percentage of employees attending lectures)

100

1009Restricted stock remuneration
Restricted stocks will be granted to all the employees and directors of thegroup as an incentive to raise the corporate value sustainably and promotevalue sharing with shareholders.
Purpose

Foster consciousness to raise the corporate value and promote value
sharing with shareholders

Grantee

637 employees and directors of the group (including contract
employees and part-timers)

Number of share tobe allotted

250 shares per head (equivalent to Y257,500 at the closing price on July30th)
159,250 shares in total

Disposal date

September 29, 2023

Lifting date of thetransfer restriction

July 1, 2024
10Disclaimer
This material was prepared based on the information available and the views held at the time it was made. Statements in thismaterial that are not historical facts, including but not limited to plans, forecasts and strategies are “forward-looking statements.”
Forward-looking statements are by their nature subject to various risks and uncertainties, including but not limited to a decline ingeneral economic conditions, general market conditions, technological developments, changes in customer demand for products
and services, increased competition, and other important factors, each of which may cause actual results and future developments
to differ materially from those expressed or implied in any forward-looking statement.
With the passage of time, the information in this material (including but not limited to forward-looking statements) could besuperseded or cease to be accurate. WIN-Partners Co., Ltd. disclaims any obligation or responsibility to update, revise, orsupplement any forward-looking statement or other information in any material or generally to any extent. The utilization of or
reliance on the information in this material is at the user’s own risk.

Contact
WIN-Partners Co., Ltd.
Investor Relations
Phone: +81-3-3548-0790
http://www.win-partners.co.jp